<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cytometry A</journal-id><journal-id journal-id-type="iso-abbrev">Cytometry A</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Cytometry. Part A : the journal of the International Society for Analytical Cytology</journal-title></journal-title-group><issn pub-type="ppub">1552-4922</issn><issn pub-type="epub">1552-4930</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12244433</article-id><article-id pub-id-type="pmcid-ver">PMC12244433.1</article-id><article-id pub-id-type="pmcaid">12244433</article-id><article-id pub-id-type="pmcaiid">12244433</article-id><article-id pub-id-type="manuscript-id">NIHMS2088207</article-id><article-id pub-id-type="pmid">36470845</article-id><article-id pub-id-type="doi">10.1002/cyto.a.24707</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS2088207</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA2088207</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>OMIP-087: Thirty-two parameter mass cytometry panel to assess human CD4 and CD8 T cell activation, memory subsets, and helper subsets</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-5722-3470</contrib-id><name name-style="western"><surname>Sponaugle</surname><given-names initials="A">Alexis</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Abad-Fernandez</surname><given-names initials="M">Maria</given-names></name><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Goonetilleke</surname><given-names initials="N">Nilu</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref></contrib></contrib-group><aff id="A1"><label>1</label>Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA</aff><aff id="A2"><label>2</label>Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States</aff><author-notes><fn fn-type="con" id="FN1"><p id="P1">AUTHOR CONTRIBUTIONS</p><p id="P2"><bold>Alexis Sponaugle</bold>: Conceptualization, methodology, data curation, investigation, validation, formal analysis, visualization, writing - original draft, writing - review &amp; editing. <bold>Maria Abad-Fernandez</bold>: methodology, validation, writing - review &amp; editing. <bold>Nilu Goonetilleke</bold>: Conceptualization, data curation, supervision, funding acquisition, resources, writing - review &amp; editing.</p></fn><corresp id="CR1"><bold>Correspondence</bold>: Nilu Goonetilleke, Department of Microbiology and Immunology and Department of Medicine, University of North Carolina at Chapel Hill, 120 Mason Farm, Rd. Chapel Hill, NC 27514, USA. <email>nilu_goonetilleke@med.unc.edu</email></corresp></author-notes><pub-date pub-type="ppub"><month>3</month><year>2023</year></pub-date><pub-date pub-type="epub"><day>05</day><month>12</month><year>2022</year></pub-date><volume>103</volume><issue>3</issue><issue-id pub-id-type="pmc-issue-id">492598</issue-id><fpage>184</fpage><lpage>188</lpage><pub-history><event event-type="nihms-submitted"><date><day>19</day><month>06</month><year>2025</year></date></event><event event-type="pmc-release"><date><day>10</day><month>07</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>10</day><month>07</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-07-11 11:25:38.883"><day>11</day><month>07</month><year>2025</year></date></event></pub-history><permissions><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-2088207.pdf"/><abstract id="ABS1"><p id="P3">We developed a highly reproducible 32-marker mass cytometry panel able to measure all canonical immune lineages and perform detailed characterization of both CD4 and CD8 T cells in human peripheral blood mononuclear cells. In this panel, we identify six different T cell memory subsets, as well as markers of activation, cell cycling, and survival. In addition, this panel classifies all major CD4 T cell helper subsets. This panel enables detailed monitoring of CD4 and CD8 T cells in the context of infectious disease, cancer or autoimmunity with limited patient sample use. Detailed methods for standardization and optimization of the panel can be found in <xref rid="SD12" ref-type="supplementary-material">Supporting Information</xref>.</p></abstract><kwd-group><kwd>CD4 T cells</kwd><kwd>CD8 T cells</kwd><kwd>mass cytometry</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="S1"><label>1 |</label><title>BRIEF NARRATIVE</title><p id="P4">This study describes the development of a panel for detailed investigation of T cell phenotypes and frequencies in people. Our interest is in understanding CD4 T cell memory recovery in people living with HIV (PLWH) following antiretroviral therapy (ART) initiation [<xref rid="R1" ref-type="bibr">1</xref>&#8211;<xref rid="R4" ref-type="bibr">4</xref>]. HIV infection greatly depletes CD4 T cell numbers but also dysregulates CD4 T cell memory formation [<xref rid="R5" ref-type="bibr">5</xref>]. Moreover, the volume of blood available for study is often limited in these populations. To address the challenges of both sample limitation and depleted CD4 T cell numbers in PLWH we developed a CD4 T cell focused mass cytometry panel. This panel will also be useful for studies in the areas of burn recovery, transplantation and cancer, which often involve patients who are immunosuppressed and therefore have limited number of T cells. This panel allows the identification of helper subsets-T<sub>H1</sub>, T<sub>H2</sub>, T<sub>H17</sub>, T<sub>H17.1</sub>, T<sub>H9</sub>, T<sub>H22</sub>, T<sub>reg</sub>, T<sub>FH</sub>, memory subsets (recent thymic emigrants, na&#239;ve, stem cell memory, central memory, transitional memory, effector memory, terminal effector), activation markers (CD25, HLA-DR, CD38), activation/exhaustion marker PD-1, survival marker Bcl-2, and cell cycling marker Ki-67 (<xref rid="T1" ref-type="table">Table 1</xref>). While the 32 parameter panel described here can be used to investigate many aspects of T cell biology, it can also be easily adapted. For example, the 50 marker capacity of mass cytometry [<xref rid="R6" ref-type="bibr">6</xref>] allows markers to be added as per researchers&#8217; needs. Alternatively, components of this panel can be used to build very distinct phenotyping panels. For example, the lineage markers described here could be used as the backbone in a new panel.</p><p id="P5">This panel identifies multiple cell lineages (B cells, NK cells, monocytes, CD4 T cells, CD8 T cells and TCR&#947;&#948; T cells). While the gating strategy presented here (<xref rid="F1" ref-type="fig">Figure 1</xref>) largely focuses on CD4 and CD8 T cells, this panel can also be used to identify B cells (CD19<sup>+</sup>), plasmablasts (CD19<sup>+</sup>CD27<sup>+</sup>CD38<sup>hi</sup>), NK cell subsets (CD56<sup>bright</sup>CD16<sup>&#8722;</sup>, CD56<sup>dim</sup>CD16<sup>+</sup>CD57<sup>&#8722;</sup>, and CD56<sup>dim</sup>CD16<sup>+</sup>CD57<sup>+</sup>) and monocyte subsets (classical (CD14<sup>+</sup>CD16<sup>&#8722;</sup>), nonclassical (CD14<sup>dim</sup>CD16<sup>+</sup>), and intermediate (CD14<sup>+</sup>CD16<sup>+</sup>)). CD4 T cells were identified as CD3 + CD4+, CD8 T cells as CD3 + CD8+ and TCR&#947;&#948; T cells as CD3 + TCR&#947;&#948;+. CD4 T cell memory subsets were determined using markers CD45RA, CCR7, CD28, CD95, CD99, and CCR10: na&#239;ve (CD45RA + CCR7 + CD28 + CD95&#8722;), stem cell memory (CD45RA + CCR7 + CD28 + CD95+), central memory (CD45RA-CCR7 + CD28 + CD95+), transitional memory (CD45RA-CCR7-CD28 + CD95+), effector memory (CD45RA-CCR7-CD28-CD95+), and terminal effectors (CD45RA + CCR7-CD28-CD95+). CD99 and CCR10 have been shown to be enriched on memory CD4 T cells [<xref rid="R7" ref-type="bibr">7</xref>]. Helper subsets were defined using OMIP-017 gating strategy using the chemokine receptors CCR4, CXCR3, CCR10, and CCR6 [<xref rid="R8" ref-type="bibr">8</xref>]. Regulatory T cells (T<sub>reg</sub>) were identified as CD25<sup>HI</sup>CD127-FoxP3+ and follicular helper T cells (T<sub>FH</sub>) were defined as CXCR5 + CD45RA-. Activation markers CD25, Ki-67, CD38, CD57, and HLA-DR were examined on CD4 T cells as well as the activation/exhaustion marker PD-1. Finally, we examined survival marker Bcl-2 and long lived memory marker CD127 on CD4 T cells.</p><p id="P6">To optimize this panel we first assigned each marker to a metal isotope, choosing lower signal isotopes for highly expressed markers and higher signal isotopes for lowly expressed markers. In addition, while spill over in mass cytometry is minimal, it can occur due to overabundance of an ion spreading into mass + 1 or mass-1 channels, oxide formation or isotopic impurities. Therefore, lowly expressed markers were not place in mass + 1, mass-1, or mass-16 of a highly expressed marker [<xref rid="R9" ref-type="bibr">9</xref>]. We experimentally confirmed that we did not have spill over from one channel into another using the method recommended by Fluidigm and detailed further in the <xref rid="SD12" ref-type="supplementary-material">Supporting Information</xref>, online portion of this OMIP. Because spill over is predictable, once we experimentally confirmed that there was no spill over in our panel, metal minus one controls (similar to fluorescent minus one controls in flow cytometry) are not necessary, further reducing cell requirements. To effectively capture small populations such as stem cell memory T cells, we routinely collected 700,000 events (on average 380,000 DNA+ live cells) with a minimum of 20,000 CD4 T cells collected. This cell number also allows for detection of subpopulations within CD4 T cells at a frequency of 1% with a coefficient of variation of 7% [<xref rid="R10" ref-type="bibr">10</xref>]. To account for batch effects, cryopreserved PBMCs derived from a single buffy coat from the same healthy donor were spiked (1:5 reference: sample) into every sample for every experiment and labeled with CD45 111Cd [<xref rid="R11" ref-type="bibr">11</xref>, <xref rid="R12" ref-type="bibr">12</xref>]. Using these methods, we have developed a highly reproducible and robust mass cytometry panel capable of detecting all major cell lineages and detailed characterization of T cell subsets that can be used for clinical trials investigating cancer, infectious disease and autoimmunity.</p></sec><sec id="S2"><label>2 |</label><title>SIMILARITY TO RELATED OMIPS</title><p id="P7">This mass cytometry panel contains a range of cell surface markers allowing for the identification of all major leukocyte subsets and CD4 and CD8 T cell subpopulations. Both OMIP-034 and OMIP-045 employ mass cytometry. However, this panel has a larger focus on T cell subsets compared to OMIP-034 [<xref rid="R13" ref-type="bibr">13</xref>]. OMIP-045 was developed to study head and neck squamous cell carcinoma (HNSCC) and therefore is largely focused on signaling pathways associated with HNSCC [<xref rid="R14" ref-type="bibr">14</xref>]. While some of the same lineages markers are used, there is very little overlap in markers between OMIP-045 and this panel. This panel is partially overlaps with OMIP-001, 003, &#8722;004, &#8722;006, &#8722;007, &#8722;010, &#8722;013, &#8722;015, &#8722;017, &#8722;023, &#8722;024, &#8722;030, &#8722;042, &#8722;060, &#8722;063, &#8722;067, &#8722;069, &#8722;078, and &#8722; 080. These are flow cytometry panels that use the same antibody but are fluorophore tagged rather than heavy metal tagged to identify leukocyte subsets.</p><p id="P8">Cross reference: OMIP-017, &#8722;034, &#8722;063, &#8722;069, &#8722;078, 080.</p></sec><sec id="S3"><label>3 |</label><title>HUMAN SAMPLES</title><p id="P9">The University of North Carolina at Chapel Hill Biomedical Institutional Review Board (IRB) approved review and implementation of all protocols utilized for the collection of samples for this analysis. All participants provided informed consent.</p></sec><sec sec-type="supplementary-material" id="SM1"><title>Supplementary Material</title><supplementary-material id="SD1" position="float" content-type="local-data" orientation="portrait"><label>Figure 1. Biological Controls</label><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="NIHMS2088207-supplement-Figure_1__Biological_Controls.tif" id="d67e258" position="anchor" orientation="portrait"/></supplementary-material><supplementary-material id="SD2" position="float" content-type="local-data" orientation="portrait"><label>Figure 2. Reference PBMCS</label><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="NIHMS2088207-supplement-Figure__2__Reference_PBMCS.tif" id="d67e261" position="anchor" orientation="portrait"/></supplementary-material><supplementary-material id="SD3" position="float" content-type="local-data" orientation="portrait"><label>Figure 3. Titrations</label><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="NIHMS2088207-supplement-Figure_3__Titrations.tif" id="d67e264" position="anchor" orientation="portrait"/></supplementary-material><supplementary-material id="SD4" position="float" content-type="local-data" orientation="portrait"><label>Figure 6. FoxP3 Buffers</label><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="NIHMS2088207-supplement-Figure_6__FoxP3_Buffers.tif" id="d67e267" position="anchor" orientation="portrait"/></supplementary-material><supplementary-material id="SD5" position="float" content-type="local-data" orientation="portrait"><label>Figure 4. Spill Over</label><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="NIHMS2088207-supplement-Figure_4__Spill_Over.tif" id="d67e270" position="anchor" orientation="portrait"/></supplementary-material><supplementary-material id="SD6" position="float" content-type="local-data" orientation="portrait"><label>Figure 5. Same Donor and 5 HD</label><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="NIHMS2088207-supplement-Figure_5__Same_Donor_and_5_HD.tif" id="d67e273" position="anchor" orientation="portrait"/></supplementary-material><supplementary-material id="SD7" position="float" content-type="local-data" orientation="portrait"><label>Figure 7. Clean up data</label><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="NIHMS2088207-supplement-Figure_7__Clean_up_data.tif" id="d67e276" position="anchor" orientation="portrait"/></supplementary-material><supplementary-material id="SD8" position="float" content-type="local-data" orientation="portrait"><label>Figure 8. viSNE</label><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="NIHMS2088207-supplement-Figure_8__viSNE.tif" id="d67e279" position="anchor" orientation="portrait"/></supplementary-material><supplementary-material id="SD9" position="float" content-type="local-data" orientation="portrait"><label>Online Table 1</label><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="NIHMS2088207-supplement-Online_Table_1.docx" id="d67e282" position="anchor" orientation="portrait"/></supplementary-material><supplementary-material id="SD10" position="float" content-type="local-data" orientation="portrait"><label>Online Table 2</label><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="NIHMS2088207-supplement-Online_Table_2.docx" id="d67e285" position="anchor" orientation="portrait"/></supplementary-material><supplementary-material id="SD11" position="float" content-type="local-data" orientation="portrait"><label>MIFlowCyt Item Checklist</label><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="NIHMS2088207-supplement-MIFlowCyt_Item_Checklist.doc" id="d67e289" position="anchor" orientation="portrait"/></supplementary-material><supplementary-material id="SD12" position="float" content-type="local-data" orientation="portrait"><label>OMIP online</label><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="NIHMS2088207-supplement-OMIP_online.docx" id="d67e292" position="anchor" orientation="portrait"/></supplementary-material><p id="P15">Additional <xref rid="SD12" ref-type="supplementary-material">supporting information</xref> can be found online in the <xref rid="SD12" ref-type="supplementary-material">Supporting Information</xref> section at the end of this article.</p></sec></body><back><ack id="S4"><title>ACKNOWLEDGMENTS</title><p id="P10">We would like to thank the University of North Carolina Mass Cytometry Core (UNC Cancer Center Core Support Grant #P30CA016086) for running our samples. Nilu Goonetilleke is the Director of the UNC Immunology Specialty Laboratory in the AIDS Clinical Trials Group (ACTG).</p><sec id="S5"><title>Funding information</title><p id="P11">AIDS Clinical Trials Group, Grant/Award Number: 2UM1AI106701&#8211;08; National Institutes of Health; UNC Cancer Center Core Support, Grant/Award Number: P30CA016086; NIAID, Grant/Award Number: 5U01AI131310</p></sec></ack><fn-group><fn fn-type="COI-statement" id="FN2"><p id="P12">CONFLICT OF INTEREST</p><p id="P13">The authors declare no conflict of interest.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="R1"><label>1.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Abrahams</surname><given-names>MR</given-names></name>, <name name-style="western"><surname>Joseph</surname><given-names>SB</given-names></name>, <name name-style="western"><surname>Garrett</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Tyers</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Moeser</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Archin</surname><given-names>N</given-names></name>, <etal/><article-title>The replication-competent HIV-1 latent reservoir is primarily established near the time of therapy initiation</article-title>. <source>Sci Transl Med</source>. <year>2019</year>;<volume>eaaw5589</volume>:<fpage>11</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/scitranslmed.aaw5589</pub-id><pub-id pub-id-type="pmcid">PMC7233356</pub-id><pub-id pub-id-type="pmid">31597754</pub-id></mixed-citation></ref><ref id="R2"><label>2.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Goonetilleke</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Clutton</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Swanstrom</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Joseph</surname><given-names>SB</given-names></name>. <article-title>Blocking formation of the stable HIV reservoir: a new perspective for HIV-1 cure</article-title>. <source>Front Immunol</source>. <year>2019</year>;<volume>10</volume>:<fpage>1966</fpage>.<pub-id pub-id-type="pmid">31507594</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2019.01966</pub-id><pub-id pub-id-type="pmcid">PMC6714000</pub-id></mixed-citation></ref><ref id="R3"><label>3.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Brodin</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Zanini</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Thebo</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Lanz</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Bratt</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Neher</surname><given-names>RA</given-names></name>, <etal/><article-title>Establishment and stability of the latent HIV-1 DNA reservoir</article-title>. <source>Elife</source>. <year>2016</year>;<volume>5</volume>:<fpage>e18889</fpage>.<pub-id pub-id-type="pmid">27855060</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7554/eLife.18889</pub-id><pub-id pub-id-type="pmcid">PMC5201419</pub-id></mixed-citation></ref><ref id="R4"><label>4.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Brooks</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Jones</surname><given-names>BR</given-names></name>, <name name-style="western"><surname>Dilernia</surname><given-names>DA</given-names></name>, <name name-style="western"><surname>Wilkins</surname><given-names>DJ</given-names></name>, <name name-style="western"><surname>Claiborne</surname><given-names>DT</given-names></name>, <name name-style="western"><surname>McInally</surname><given-names>S</given-names></name>, <etal/><article-title>HIV-1 variants are archived throughout infection and persist in the reservoir</article-title>. <source>PLoS Pathog</source>. <year>2020</year>;<volume>16</volume>:<fpage>e1008378</fpage>.<pub-id pub-id-type="pmid">32492044</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.ppat.1008378</pub-id><pub-id pub-id-type="pmcid">PMC7295247</pub-id></mixed-citation></ref><ref id="R5"><label>5.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Okoye</surname><given-names>AA</given-names></name>, <name name-style="western"><surname>Picker</surname><given-names>LJ</given-names></name>. <article-title>CD4(+) T-cell depletion in HIV infection: mechanisms of immunological failure</article-title>. <source>Immunol Rev</source>. <year>2013</year>;<volume>254</volume>:<fpage>54</fpage>&#8211;<lpage>64</lpage>.<pub-id pub-id-type="pmid">23772614</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/imr.12066</pub-id><pub-id pub-id-type="pmcid">PMC3729334</pub-id></mixed-citation></ref><ref id="R6"><label>6.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Nicholas</surname><given-names>KJ</given-names></name>, <name name-style="western"><surname>Greenplate</surname><given-names>AR</given-names></name>, <name name-style="western"><surname>Flaherty</surname><given-names>DK</given-names></name>, <name name-style="western"><surname>Matlock</surname><given-names>BK</given-names></name>, <name name-style="western"><surname>Juan</surname><given-names>JS</given-names></name>, <name name-style="western"><surname>Smith</surname><given-names>RM</given-names></name>, <etal/><article-title>Multiparameter analysis of stimulated human peripheral blood mononuclear cells: a comparison of mass and fluorescence cytometry</article-title>. <source>Cytometry A</source>. <year>2016</year>;<volume>89</volume>:<fpage>271</fpage>&#8211;<lpage>80</lpage>.<pub-id pub-id-type="pmid">26599989</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cyto.a.22799</pub-id><pub-id pub-id-type="pmcid">PMC4808335</pub-id></mixed-citation></ref><ref id="R7"><label>7.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Song</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Sengupta</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Khoruzhenko</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Welsh</surname><given-names>RA</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Kumar</surname><given-names>MR</given-names></name>, <etal/><article-title>Multiple genetic programs contribute to CD4 T cell memory differentiation and longevity by maintaining T cell quiescence</article-title>. <source>Cell Immunol</source>. <year>2020</year>;<volume>357</volume>:<fpage>104210</fpage>.<pub-id pub-id-type="pmid">32987276</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cellimm.2020.104210</pub-id><pub-id pub-id-type="pmcid">PMC7737224</pub-id></mixed-citation></ref><ref id="R8"><label>8.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Mahnke</surname><given-names>YD</given-names></name>, <name name-style="western"><surname>Beddall</surname><given-names>MH</given-names></name>, <name name-style="western"><surname>Roederer</surname><given-names>M</given-names></name>. <article-title>OMIP-017: human CD4(+) helper T-cell subsets including follicular helper cells</article-title>. <source>Cytometry A</source>. <year>2013</year>;<volume>83</volume>(<issue>5</issue>):<fpage>439</fpage>&#8211;<lpage>40</lpage>.<pub-id pub-id-type="pmid">23450796</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cyto.a.22269</pub-id><pub-id pub-id-type="pmcid">PMC4347402</pub-id></mixed-citation></ref><ref id="R9"><label>9.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Leipold</surname><given-names>MD</given-names></name>, <name name-style="western"><surname>Newell</surname><given-names>EW</given-names></name>, <name name-style="western"><surname>Maecker</surname><given-names>HT</given-names></name>. <article-title>Multiparameter phenotyping of human PBMCs using mass cytometry</article-title>. <source>Methods Mol Biol</source>. <year>2015</year>;<volume>1343</volume>:<fpage>81</fpage>&#8211;<lpage>95</lpage>.<pub-id pub-id-type="pmid">26420710</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/978-1-4939-2963-4_7</pub-id><pub-id pub-id-type="pmcid">PMC4748856</pub-id></mixed-citation></ref><ref id="R10"><label>10.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Marvin</surname><given-names>J</given-names></name>. <source>How many cells should I count?</source><year>2013</year>.</mixed-citation></ref><ref id="R11"><label>11.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Kleinsteuber</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Corleis</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Rashidi</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Nchinda</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Lisanti</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Cho</surname><given-names>JL</given-names></name>, <etal/><article-title>Standardization and quality control for high-dimensional mass cytometry studies of human samples</article-title>. <source>Cytometry A</source>. <year>2016</year>;<volume>89</volume>:<fpage>903</fpage>&#8211;<lpage>13</lpage>.<pub-id pub-id-type="pmid">27575385</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cyto.a.22935</pub-id><pub-id pub-id-type="pmcid">PMC5495108</pub-id></mixed-citation></ref><ref id="R12"><label>12.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Sahaf</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Rahman</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Maecker</surname><given-names>HT</given-names></name>, <name name-style="western"><surname>Bendall</surname><given-names>SC</given-names></name>. <article-title>High-parameter immune profiling with CyTOF. Methods in molecular biology</article-title>. <source>Methods Mol Biol</source>. <year>2020</year>;<volume>2055</volume>:<fpage>351</fpage>&#8211;<lpage>68</lpage>.<pub-id pub-id-type="pmid">31502160</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/978-1-4939-9773-2_16</pub-id><pub-id pub-id-type="pmcid">PMC7232871</pub-id></mixed-citation></ref><ref id="R13"><label>13.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Baumgart</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Peddinghaus</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Schulte-Wrede</surname><given-names>U</given-names></name>, <name name-style="western"><surname>Mei</surname><given-names>HE</given-names></name>, <name name-style="western"><surname>Gr&#252;tzkau</surname><given-names>A</given-names></name>. <article-title>OMIP-034: comprehensive immune phenotyping of human peripheral leukocytes by mass cytometry for monitoring immunomodulatory therapies</article-title>. <source>Cytometry A</source>. <year>2017</year>;<volume>91</volume>:<fpage>34</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">27362704</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cyto.a.22894</pub-id></mixed-citation></ref><ref id="R14"><label>14.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Brodie</surname><given-names>TM</given-names></name>, <name name-style="western"><surname>Tosevski</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Medov&#225;</surname><given-names>M</given-names></name>. <article-title>OMIP-045: characterizing human head and neck tumors and cancer cell lines with mass cytometry</article-title>. <source>Cytometry A</source>. <year>2018</year>;<volume>93</volume>:<fpage>406</fpage>&#8211;<lpage>10</lpage>.<pub-id pub-id-type="pmid">29648681</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cyto.a.23336</pub-id></mixed-citation></ref></ref-list></back><floats-group><fig position="float" id="F1" orientation="portrait"><label>FIGURE 1</label><caption><p id="P16">Manual gating of OMIP. (A) Canonical cell lineages. First, all leukocyte populations were identified as CD45+ (89Y for sample of interest and 111Cd for reference cells). Dendritic cells (DCs) were identified as CD14-CD19-CD3-HLA-DR + CD11c+, monocytes as CD3-CD19-CD14+, B cells as CD3-CD14-CD19+, and NK cells as CD3-CD14-CD19-CD16 + CD56+. CD4 T cells identified as CD3 + CD4+, CD8 T cells as CD3 + CD8+, and TCR&#947;&#948; T cells as CD3 + TCR&#947;&#948;+. (B) CD4 T cell memory subsets were determined using markers CD45RA, CCR7, CD28, CD95, CD99, and CCR10. Na&#239;ve T cells defined as CD45RA + CCR7 + CD28 + CD95&#8722;, stem cell memory as CD45RA + CCR7 + CD28 + CD95+, central memory as CD45RA-CCR7 + CD28 + CD95+, transitional memory as CD45RA-CCR7-CD28 + CD95+, effector memory as CD45RA-CCR7-CD28-CD95+, and terminal effectors as CD45RA + CCR7-CD28-CD95+. CD99hi and CCR10+ are enriched on memory CD4 T cells. (C) CD4 T cell helper subsets. Helper subsets were defined using OMIP-017 gating strategy using the chemokine receptors CCR4, CXCR3, CCR10, and CCR6. T<sub>reg</sub> were identified as CD25<sup>HI</sup>CD127-FoxP3+ and T<sub>FH</sub> were defined as CXCR5+. (D) Activation markers CD25, Ki-67, CD38, CD57, and HLA-DR on CD4 T cells. Activation/exhaustion marker PD-1, survival marker Bcl-2 and long lived memory marker CD127 on CD4 T cells</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihms-2088207-f0001.jpg"/></fig><table-wrap position="float" id="T1" orientation="landscape"><label>TABLE 1</label><caption><p id="P18">Antibodies uses for OMIP-087</p></caption><table frame="hsides" rules="rows"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Specificity</th><th align="left" valign="top" rowspan="1" colspan="1">Clone</th><th align="left" valign="top" rowspan="1" colspan="1">Metal isotope</th><th align="left" valign="top" rowspan="1" colspan="1">Purpose</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">CD45</td><td align="left" valign="top" rowspan="1" colspan="1">HI30</td><td align="left" valign="top" rowspan="1" colspan="1">89Y</td><td align="left" valign="top" rowspan="1" colspan="1">Pan leukocytes</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CD45</td><td align="left" valign="top" rowspan="1" colspan="1">HI30</td><td align="left" valign="top" rowspan="1" colspan="1">111Cd</td><td align="left" valign="top" rowspan="1" colspan="1">Pan leukocytes</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CD56 (NCAM)</td><td align="left" valign="top" rowspan="1" colspan="1">N901</td><td align="left" valign="top" rowspan="1" colspan="1">176Yb</td><td align="left" valign="top" rowspan="1" colspan="1">NK cells</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CD16</td><td align="left" valign="top" rowspan="1" colspan="1">3G8</td><td align="left" valign="top" rowspan="1" colspan="1">209Bi</td><td align="left" valign="top" rowspan="1" colspan="1">NK cells</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CD11c</td><td align="left" valign="top" rowspan="1" colspan="1">3.9</td><td align="left" valign="top" rowspan="1" colspan="1">146Nd</td><td align="left" valign="top" rowspan="1" colspan="1">Dendritic cells</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CD14</td><td align="left" valign="top" rowspan="1" colspan="1">M5E2</td><td align="left" valign="top" rowspan="1" colspan="1">151Eu</td><td align="left" valign="top" rowspan="1" colspan="1">Monocytes</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CD19</td><td align="left" valign="top" rowspan="1" colspan="1">HIB19</td><td align="left" valign="top" rowspan="1" colspan="1">142Nd</td><td align="left" valign="top" rowspan="1" colspan="1">B cells</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CD3&#949;</td><td align="left" valign="top" rowspan="1" colspan="1">UCHT1</td><td align="left" valign="top" rowspan="1" colspan="1">115In</td><td align="left" valign="top" rowspan="1" colspan="1">T cells</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">TCR&#947;&#948;</td><td align="left" valign="top" rowspan="1" colspan="1">B1</td><td align="left" valign="top" rowspan="1" colspan="1">173Yb</td><td align="left" valign="top" rowspan="1" colspan="1">TCR&#947;&#948; T cells</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CD4</td><td align="left" valign="top" rowspan="1" colspan="1">RPA-T4</td><td align="left" valign="top" rowspan="1" colspan="1">145Nd</td><td align="left" valign="top" rowspan="1" colspan="1">T helper cells</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CD8a</td><td align="left" valign="top" rowspan="1" colspan="1">SK1</td><td align="left" valign="top" rowspan="1" colspan="1">168Er</td><td align="left" valign="top" rowspan="1" colspan="1">CD8 T cells</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CD45RA</td><td align="left" valign="top" rowspan="1" colspan="1">HI100</td><td align="left" valign="top" rowspan="1" colspan="1">143Nd</td><td align="left" valign="top" rowspan="1" colspan="1">T cell memory</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CCR7</td><td align="left" valign="top" rowspan="1" colspan="1">G043H7</td><td align="left" valign="top" rowspan="1" colspan="1">167Er</td><td align="left" valign="top" rowspan="1" colspan="1">T cell memory</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CD28</td><td align="left" valign="top" rowspan="1" colspan="1">CD28.2</td><td align="left" valign="top" rowspan="1" colspan="1">160Gd</td><td align="left" valign="top" rowspan="1" colspan="1">T cell memory</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CD27</td><td align="left" valign="top" rowspan="1" colspan="1">L128</td><td align="left" valign="top" rowspan="1" colspan="1">158Gd</td><td align="left" valign="top" rowspan="1" colspan="1">T cell memory</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CD95/Fas</td><td align="left" valign="top" rowspan="1" colspan="1">DX2</td><td align="left" valign="top" rowspan="1" colspan="1">164Dy</td><td align="left" valign="top" rowspan="1" colspan="1">T cell memory</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CD99</td><td align="left" valign="top" rowspan="1" colspan="1">3B2/TA8</td><td align="left" valign="top" rowspan="1" colspan="1">147Sm</td><td align="left" valign="top" rowspan="1" colspan="1">T cell memory</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CD127 (IL-7Ra)</td><td align="left" valign="top" rowspan="1" colspan="1">A019D5</td><td align="left" valign="top" rowspan="1" colspan="1">165Ho</td><td align="left" valign="top" rowspan="1" colspan="1">T cell memory</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CCR6</td><td align="left" valign="top" rowspan="1" colspan="1">11A9</td><td align="left" valign="top" rowspan="1" colspan="1">141Pr</td><td align="left" valign="top" rowspan="1" colspan="1">Th subsets</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CCR4</td><td align="left" valign="top" rowspan="1" colspan="1">L291H4</td><td align="left" valign="top" rowspan="1" colspan="1">149Sm</td><td align="left" valign="top" rowspan="1" colspan="1">Th subsets</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CXCR5</td><td align="left" valign="top" rowspan="1" colspan="1">RF8B2</td><td align="left" valign="top" rowspan="1" colspan="1">153Eu</td><td align="left" valign="top" rowspan="1" colspan="1">Th subsets</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CXCR3</td><td align="left" valign="top" rowspan="1" colspan="1">G025H7</td><td align="left" valign="top" rowspan="1" colspan="1">156Gd</td><td align="left" valign="top" rowspan="1" colspan="1">Th subsets</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CCR5</td><td align="left" valign="top" rowspan="1" colspan="1">NP-6G4</td><td align="left" valign="top" rowspan="1" colspan="1">171Yb</td><td align="left" valign="top" rowspan="1" colspan="1">Th subsets</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CCR10</td><td align="left" valign="top" rowspan="1" colspan="1">314,305</td><td align="left" valign="top" rowspan="1" colspan="1">175Lu</td><td align="left" valign="top" rowspan="1" colspan="1">Th subsets</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">FoxP3</td><td align="left" valign="top" rowspan="1" colspan="1">259D/C7</td><td align="left" valign="top" rowspan="1" colspan="1">159 Tb</td><td align="left" valign="top" rowspan="1" colspan="1">Treg</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Bcl-2</td><td align="left" valign="top" rowspan="1" colspan="1">100</td><td align="left" valign="top" rowspan="1" colspan="1">152Sm</td><td align="left" valign="top" rowspan="1" colspan="1">Survival</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CD279 (PD-1)</td><td align="left" valign="top" rowspan="1" colspan="1">EH12.2H7</td><td align="left" valign="top" rowspan="1" colspan="1">155Gd</td><td align="left" valign="top" rowspan="1" colspan="1">Activation/Exhaustion</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Ki-67</td><td align="left" valign="top" rowspan="1" colspan="1">B56</td><td align="left" valign="top" rowspan="1" colspan="1">162Dy</td><td align="left" valign="top" rowspan="1" colspan="1">Cell cycling</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CD57</td><td align="left" valign="top" rowspan="1" colspan="1">HCD57</td><td align="left" valign="top" rowspan="1" colspan="1">166Er</td><td align="left" valign="top" rowspan="1" colspan="1">Senescence</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CD25 (IL-2R)</td><td align="left" valign="top" rowspan="1" colspan="1">2A3</td><td align="left" valign="top" rowspan="1" colspan="1">169Tm</td><td align="left" valign="top" rowspan="1" colspan="1">Activation</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HLA-DR</td><td align="left" valign="top" rowspan="1" colspan="1">L243</td><td align="left" valign="top" rowspan="1" colspan="1">170Er</td><td align="left" valign="top" rowspan="1" colspan="1">Activation</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CD38</td><td align="left" valign="top" rowspan="1" colspan="1">HIT2</td><td align="left" valign="top" rowspan="1" colspan="1">172Yb</td><td align="left" valign="top" rowspan="1" colspan="1">Activation</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CD31</td><td align="left" valign="top" rowspan="1" colspan="1">Wm59</td><td align="left" valign="top" rowspan="1" colspan="1">144Nd</td><td align="left" valign="top" rowspan="1" colspan="1">Recent thymic emigrants</td></tr></tbody></table></table-wrap></floats-group></article></pmc-articleset>